Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 15

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 15
---
 |   |      |     | $ | 1.835 |
| Net tangible book value per share as of March 31, 2025                             |     | $ | 0.43 |     |   |       |
| Increase in net tangible book value per share after giving effect to this offering |     | $ | 0.53 |     |   |       |
| Adjusted net tangible book value per share after giving effect to this offering    |     |   |      |     | $ |  0.96 |
| Dilution per share to new investors                                                |     |   |      |     | $ | 0.875 |

The as adjusted information is illustrative only and will vary based on the actual sale price to the public, the actual number of shares sold and other terms of the offering determined at the time our ordinary shares are sold pursuant to this prospectus. The shares sold in this offering, if any, will be sold from time to time at various prices. The above is based on our actual ordinary shares outstanding as of March 31, 2025 and excludes:

| • | 7,795,198 of our ordinary shares issuable upon the exercise of options outstanding as of March 31, 2025, at a weighted average exercise price of $2.38 per ordinary share; |

| • | 186,936 of our ordinary shares issuable upon the exercise of restricted share units outstanding as of March 31, 2025; |

| • | 1,254,490 of our ordinary shares issuable upon the exercise of pre-funded warrants outstanding as of March 31, 2025; |

| • | 8,344,495 of our ordinary shares issuable upon the exercise of warrants outstanding as of March 31, 2025, at a weighted average exercise price of $1.00 per ordinary share; and |

| • | 3,826,277 of our ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan as of March 31, 2025. |

To the extent that outstanding options or warrants are exercised, you may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities may result in further dilution to our shareholders